ScottM.LippmanMD

Oncology • La Jolla, CA

Head & Neck Cancer, Hematologic Oncology, Thoracic Cancer

Professor of Medicine, UC San Diego Moores Cancer Center

Join to view full profile

Dr. Lippman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lippman's full profile

Already have an account?

Office
3855 Health Sciences Dr
La Jolla, CA 92093
Phone+1 858-822-1222

Fax+1 858-822-0207

Education & Training

University of Arizona College of Medicine-TucsonFellowship, Hematology and Medical Oncology, 1985 - 1987
Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology, 1984 - 1985
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1983 - 1984
Los Angeles County-Harbor-UCLA Medical CenterInternship, Internal Medicine, 1981 - 1982
Johns Hopkins University School of MedicineClass of 1981

Certifications & Licensure

AZ State Medical License 1987 - 2025
CA State Medical License 1981 - 2025
TX State Medical License 1988 - 2013
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Association of American Physicians
Fellow (FASCO) American Society of Clinical Oncologists, 2009
Super Doctor SuperDoctors.com
Whos Who in Medicine and Healthcare Marquis Whos Who
Join now to see all

Clinical Trials

S0000 Selenium and Vitamin E in Preventing Prostate Cancer Start of enrollment: 2001 Jul 01
Completed
Phase 3
Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx Start of enrollment: 2003 Jun 01
Completed
Phase 1, Phase 2
S0437 Long-Term Follow-Up of Patients Who Were Diagnosed With Prostate Cancer on PCPT Start of enrollment: 2005 Sep 01
Terminated
Budesonide in Treating Patients With Lung Nodules at High Risk of Developing Lung Cancer Start of enrollment: 2006 Jan 01
Completed
Phase 2
Erlotinib Prevention of Oral Cancer (EPOC) Start of enrollment: 2006 Nov 03
Completed
Phase 3
Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion Start of enrollment: 2016 Jun 10
Active, not recruiting
Phase 2
Histology-Independent Study of Palbociclib in Patients With Advanced Cancer Start of enrollment: 2018 Jul 01
Withdrawn
Phase 2
Join now to see all

Publications & Presentations

PubMed

Integrated Germline and Somatic Features Reveal Divergent Immune Pathways Driving Response to Immune Checkpoint Blockade.
Timothy J Sears, Meghana S Pagadala, Andrea Castro, Ko-Han Lee, JungHo Kong
Cancer Immunology Research. 2024-12-03
Oncogenic HRAS Induces Metformin Resistance in Head and Neck Cancer by Promoting Glycolytic Metabolism.
Xingyu Wu, Sendi Rafael Adame-Garcia, Keiichi Koshizuka, Pham Thuy Tien Vo, Thomas S Hoang
Cancer Prevention Research. 2024-12-03
Reply to: Optimizing DeepHRD Interpretability for Enhanced Clinical Decision Making.
Erik N Bergstrom, Scott M Lippman, Ludmil B Alexandrov
Journal of Clinical Oncology. 2024-11-18

Journal Articles

Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction and Gastric Adenocarcinoma
Lawrence Leichman, Jason K Sicklick, Shumei Kato, Kaitlyn Kelly, Scott M Lippman, Clinical Cancer Research

Lectures

Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
University of California, San Diego, La Jolla, California - 4/6/2013
Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
University of California, San Diego, San Diego, California - 10/2/2013
Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
University of California, San Diego, San Diego, California - 10/2/2013

Authored Content

Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity TrialJune 2018
Determinants and Prognostic Value of Quality of Life in Patients with Pancreatic Ductal AdenocarcinomaFebruary 2018
Determinants and Prognostic Value of Quality of Life in Patients with Pancreatic Ductal AdenocarcinomaFebruary 2018

Press Mentions

World Economic Forum Publishes Updated List of 12 Breakthroughs in FightNovember 18th, 2024
Parsing the Genetic Drivers of Head and Neck CancersNovember 21st, 2022
Lung Cancer Screening Dramatically Increases Long-Term Survival RateNovember 21st, 2022
Join now to see all

Grant Support

M D Anderson Cancer Center Head &Neck SporeNational Cancer Institute2008–2011
CA: Administrative CoreNational Cancer Institute2008–2011
Insulin-Like Growth Factor Axis And Insulin Resistance In PcptNational Cancer Institute2007–2009
Core---Pathology/GenotypingNational Cancer Institute2007–2009
Oxidative Damage And DNA Repair In The PcptNational Cancer Institute2005–2009
Genotypic And Phenotypic Studies Of Inflammation In PcptNational Cancer Institute2005–2009
Diet And Diet-Related Factors In The PcptNational Cancer Institute2005–2009
Core--Biostatistics/Data ManagementeNational Cancer Institute2005–2009
Androgen Metabolism In The PcptNational Cancer Institute2005–2009
Molecular-Based Therapy For Oral Cancer PreventionNational Cancer Institute2004–2009
Biology Of The Prostate Cancer Prevention Trial (PCPT)National Cancer Institute2005–2008
U10 Ful Member Application Affiliated With SWOGNational Cancer Institute2004–2008
Oral Cancer Prevention With Molecular Targeting TherapyNational Cancer Institute2004–2008
Phase I &Ii Clinical Trials Of Chemopreventive AgentsNational Cancer Institute2007
MD Anderson Cancer Center Spore In Head And Neck CancerNational Cancer Institute2007
Igf-1axis And Insulin Resistance In PcptNational Cancer Institute2005–2006
Core--Pathology/GenotypingNational Cancer Institute2005–2006
Core A "Administration Core"National Cancer Institute2005
AdministrationNational Cancer Institute2004
Translational Study Of Retinoid Reversal Or Oral CarcinogenesisNational Cancer Institute1997–2002
Biologic Approach To Therapy Of Aggressive Skin CancerNational Cancer Institute1996–2002
Phase III Study Of Fenretinide In Bladder CarcinofenesisNational Cancer Institute1997–2001
Phase II Clinical Trials Of New Chemoprventive AgentsDivision Of Cancer Prevention And Control1998–1999
Chemoprevention Trial In Oral PremalignancyNational Cancer Institute1996